biote Corp. BTMD R2K
biote Corp. operates in practice-building business within the hormone optimization space. It trains physicians and nurse practitioners in hormone optimization using bioidentical hormone replacement pellet therapy in men and women experiencing hormonal imbalance. The company offers Biote Method, a comprehensive end-to-end practice building platform that provides Biote-certified practitioners with the components developed for practitioners in the hormone optimization space comprising Biote Method education, training, and certification; practice management software that allows Biote-certified practitioners to order, track, and manage hormone optimization product inventory and meet other administrative requirements; inventory management software to facilitate ordering and inventory control; and information regarding available hormone replacement therapy products, as well as digital and point-of-care marketing support. It also sells dietary supplements under the Biote brand; and sterile pellet insertion kits that is used with hormone optimization therapies for male and female patients. The company was founded in 2012 and is headquartered in Irving, Texas.
READ MORE ›Market & Price
Valuation
Profitability & Returns
Balance Sheet & Liquidity
Ownership
Financial Snapshot
Growth (CAGR)
PROS
- Healthy ROCE of 77.5%.
- Profit CAGR of 963.7% over 5 years.
CONS
- Trading 56.0% below its 52-week high.
- In a downtrend (50-DMA below 200-DMA).
* The pros and cons are auto-generated from financial metrics.
Price Chart
Technical Trend
Computed from daily close history using EMA cross, slope, and RSI signals.
Note: intraday data is not stored locally. “Hourly” uses the most recent 10 daily candles as a short-term proxy.
Fundamental Growth
No fundamental data available for this stock.
Figures from the latest reported periods. CAGR is computed across the displayed window (quarterly CAGR is annualised assuming 4 quarters per year).
Peer comparison
Peer companies in the same sector (Healthcare).
| # | Name | CMP $ | P/E | Mkt Cap | Div Yld % | ROCE % | ROE % | Rev CAGR 5Y % | Profit CAGR 5Y % |
|---|---|---|---|---|---|---|---|---|---|
| 1 | BTMD biote Corp. R2K | 2.00 | 4.65 | $71.11M | - | 77.52% | - | 5.23% | 963.67% |
| 2 | LLY Eli Lilly and Company SPX | 1,105.00 | 39.21 | $985.37B | 0.63% | 38.44% | 107.46% | 31.69% | 48.96% |
| 3 | JNJ Johnson & Johnson SPX | 225.33 | 26.11 | $542.42B | 2.38% | 23.13% | 26.42% | 5.60% | 14.32% |
| 4 | UNH UnitedHealth Group Incorporated SPX | 380.31 | 28.66 | $345.38B | 2.32% | 9.60% | 12.18% | 11.35% | -15.69% |
| 5 | MRK Merck & Co., Inc. SPX | 118.72 | 33.44 | $293.22B | 2.86% | 20.66% | 18.94% | 3.12% | 7.93% |
| 6 | TMO Thermo Fisher Scientific Inc. SPX | 492.51 | 27.11 | $183.03B | 0.38% | 9.17% | 13.52% | -0.27% | -1.19% |
| 7 | AMGN Amgen Inc. NDXSPX | 336.79 | 23.42 | $181.77B | 2.99% | 18.02% | 101.32% | 11.77% | 5.58% |
| 8 | GILD Gilead Sciences, Inc. NDXSPX | 134.43 | 18.29 | $166.90B | 2.44% | 22.92% | 43.36% | 2.57% | 22.83% |
| 9 | ISRG Intuitive Surgical, Inc. NDXSPXAI | 424.64 | 51.53 | $150.39B | - | 15.96% | 17.23% | 17.39% | 29.26% |
Quarterly Results
Figures in USD.
| Metric | Mar 2021 | Jun 2021 | Sep 2021 | Mar 2022 | Jun 2022 | Sep 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | 34.75M | 35.57M | 37.14M | 41.36M | 41.97M | 44.84M | 49.26M | 45.56M | 46.80M | 49.17M | 51.38M | 48.99M | 48.86M | 47.96M | 46.41M | 44.94M |
| Cost of Revenue | - | - | - | - | - | - | - | - | - | - | - | - | 12.61M | 13.88M | 13.54M | 14.84M | 13.98M |
| Gross Profit | - | - | - | - | - | - | - | - | - | - | - | - | 36.38M | 34.99M | 34.42M | 31.57M | 30.95M |
| Operating Expenses | - | - | - | - | - | - | - | - | - | - | - | - | 26.69M | 24.22M | 26.15M | 24.74M | 27.79M |
| Operating Income | -107.88K | 10.26M | 8.98M | 9.76M | -85.60M | 7.82M | 7.88M | 7.67M | 7.60M | 10.43M | 6.23M | 12.18M | 9.69M | 10.77M | 8.27M | 6.83M | 3.17M |
| EBITDA | - | - | - | - | - | - | - | - | - | - | - | - | 21.22M | 9.84M | 12.14M | 9.03M | 6.29M |
| Interest Expense | - | - | - | - | - | - | - | - | - | - | - | - | 2.90M | 2.85M | 2.73M | 2.47M | 1.97M |
| Pretax Income | - | - | - | - | - | - | - | - | - | - | - | - | 17.45M | 6.08M | 8.45M | 5.60M | 3.34M |
| Tax Provision | - | - | - | - | - | - | - | - | - | - | - | - | 1.62M | 2.15M | -765.00K | 2.99M | 662.00K |
| Net Income | -3.94M | 13.24M | - | 1.17M | -2.61M | 15.00K | -6.80M | -5.14M | 7.53M | -4.16M | -7.09M | 10.70M | 13.72M | 3.19M | 8.19M | 1.95M | 2.28M |
| Diluted EPS | - | - | - | - | -0.34 | 0.00 | -0.39 | -0.25 | 0.24 | -0.12 | -0.21 | 0.33 | 0.37 | 0.10 | 0.22 | 0.06 | 0.06 |
Profit & Loss (Annual)
Figures in USD.
| Metric | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|
| Revenue | - | 164.96M | 185.36M | 197.19M | 192.22M |
| Cost of Revenue | - | 54.58M | 57.88M | 58.13M | 54.86M |
| Gross Profit | - | 110.38M | 127.48M | 139.06M | 137.36M |
| Operating Expenses | - | 171.10M | 98.83M | 107.45M | 101.81M |
| Operating Income | - | -60.72M | 28.66M | 31.61M | 35.55M |
| EBITDA | - | 7.96M | 9.23M | 15.59M | 52.22M |
| Interest Expense | - | 4.05M | 6.36M | 11.00M | 10.96M |
| Pretax Income | - | 1.71M | -123.00K | 1.02M | 37.58M |
| Tax Provision | - | 388.00K | 2.68M | 970.00K | 5.99M |
| Net Income | - | -969.00K | 3.32M | 3.16M | 27.05M |
| Diluted EPS | 4.31 | -0.12 | 0.13 | 0.09 | - |
Compounded Sales Growth
| 5 Years: | 5.23% |
| 1 Year: | -8.30% |
Compounded Profit Growth
| 5 Years: | 963.67% |
| 1 Year: | -83.80% |
Stock Price Performance
| 1 Year: | -42.20% |
| 6 Months: | -21.26% |
| 3 Months: | -5.66% |
| 1 Month: | -9.91% |
Balance Sheet (Annual)
Figures in USD.
| Metric | Jul 2020 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|
| Total Assets | - | 147.50K | - | 111.64M | 155.29M | 122.37M | 107.61M |
| Current Assets | - | - | - | 101.18M | 122.34M | 68.13M | 54.67M |
| Cash & Equivalents | - | 1.59K | - | 79.23M | 89.00M | 39.34M | 24.12M |
| Inventory | - | - | - | 11.18M | 17.31M | 14.85M | 19.06M |
| Receivables | - | - | - | 6.95M | 6.81M | 7.63M | 6.87M |
| Total Liabilities | - | 122.50K | - | 169.92M | 191.84M | 224.57M | 158.01M |
| Current Liabilities | - | 122.50K | - | 18.77M | 22.21M | 51.51M | 44.99M |
| Long Term Debt | - | - | - | 112.09M | 106.63M | 101.20M | 100.78M |
| Total Debt | - | - | - | 120.43M | 114.87M | 110.86M | 109.92M |
| Total Equity | 0 | 25.00K | - | -44.46M | -29.40M | -105.93M | -58.54M |
| Shares Outstanding | - | - | - | 11.24M | 35.84M | 33.07M | 32.30M |
Cash Flows (Annual)
Figures in USD.
| Metric | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|
| Operating Cash Flow | - | -9.16M | 26.88M | 45.24M | 35.19M |
| Investing Cash Flow | - | -1.84M | -2.71M | -18.80M | -6.86M |
| Financing Cash Flow | - | 63.46M | -14.38M | -76.08M | -43.55M |
| Capital Expenditure | - | -1.84M | -2.71M | -6.96M | -6.86M |
| Free Cash Flow | - | -10.99M | 24.17M | 38.29M | 28.33M |
| Net Change in Cash | - | 52.47M | 9.79M | -49.64M | -15.22M |
| Share Buybacks | - | - | - | 5.60M | 3.37M |
| Dividends Paid | 11.40M | 12.89M | 8.69M | 4.74M | 1.73M |
Ratios (Annual)
Figures in %.
| Metric | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|
| Gross Margin % | - | 66.9% | 68.8% | 70.5% | 71.5% |
| Operating Margin % | - | -36.8% | 15.5% | 16.0% | 18.5% |
| Net Margin % | - | -0.6% | 1.8% | 1.6% | 14.1% |
| ROE % | - | 2.2% | -11.3% | -3.0% | -46.2% |
| ROCE % | - | -65.4% | 21.5% | 44.6% | 56.8% |
Shareholding Pattern
Top Institutional Holders
| # | Holder | % Held | Shares | Value |
|---|---|---|---|---|
| 1 | 325 Capital Llc | 14.32% | 4.55M | $9.10M |
| 2 | Bandera Partners LLC | 6.51% | 2.07M | $4.13M |
| 3 | Blackrock Inc. | 5.48% | 1.74M | $3.48M |
| 4 | Vanguard Capital Management LLC | 3.51% | 1.11M | $2.23M |
| 5 | Acadian Asset Management. LLC | 2.20% | 697.86K | $1.40M |
| 6 | State Street Corporation | 2.04% | 646.95K | $1.29M |
| 7 | Geode Capital Management, LLC | 1.94% | 615.66K | $1.23M |
| 8 | Dimensional Fund Advisors LP | 1.71% | 543.49K | $1.09M |
| 9 | Globeflex Capital L P | 0.86% | 272.40K | $544.80K |
| 10 | Northern Trust Corporation | 0.85% | 269.11K | $538.23K |
Analyst View
Analyst aggregate. Targets and ratings update periodically; not investment advice.
Latest News
Recent headlines for BTMD